CLINICAL_TRIALS
trial_result
· 2022-09-10
Clinical Trial Update: Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma [Phase 2]
Summary
Phase 2 trial update evaluating carfilzomib in treatment patients under 65 with high-risk smoldering multiple myeloma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: PETHEMA Foundation | Conditions: Smoldering Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING